Cord blood cells take on stomach cancer: new hope in Late-Stage trial

NCT ID NCT07212933

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it can help patients live longer and keep the cancer from growing, while checking for side effects. About 90 adults aged 18 to 70 will take part in this randomized, double-blind trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric carcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOLOGICAL THERAPY GASTRIC (STOMACH) CANCER IMMUNOTHERAPY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First＆Fifth Medical Center of Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

Contact Phone: •••-•••-•••• Email: •••••@•••••